Peterson; Ward M.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Peterson; Ward M..The latest application filed is for "method for treating cardiovascular diseases using rho kinase inhibitor compounds".

Company Profile

0.24.31

Peterson; Ward M. - Morrisville NC US
Peterson; Ward M. - Durham NC

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cytoskeletal active rho kinase inhibitor compounds, composition and use Grant 8,604,205 - Lampe , et al. December 10, 2	2013-12-10
Cytoskeletal active rho kinase inhibitor compounds, composition and use Grant 8,604,218 - Lampe , et al. December 10, 2	2013-12-10
Method For Treating Cardiovascular Diseases Using Rho Kinase Inhibitor Compounds App 20130172324 - LAMPE; John W. ; et al.	2013-07-04
Method For Treating Diseases Associated With Alterations In Cellular Integrity Using Rho Kinase Inhibitor Compounds App 20130158014 - PETERSON; Ward M. ; et al.	2013-06-20
Bifunctional Rho Kinase Inhibitor Compounds, Composition And Use App 20130131106 - LAMPE; John W. ; et al.	2013-05-23
Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds Grant 8,410,147 - Peterson , et al. April 2, 2	2013-04-02
Cytoskeletal Active Rho Kinase Inhibitor Compounds, Composition And Use App 20130012543 - LAMPE; John W. ; et al.	2013-01-10
Method For Treating Pulmonary Diseases Using Rho Kinase Inhibitor Compounds App 20130005756 - NAVRATIL; Tomas ; et al.	2013-01-03
Method for treating pulmonary diseases using rho kinase inhibitor compounds Grant 8,299,096 - Navratil , et al. October 30, 2	2012-10-30
Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds Grant 8,207,195 - Navratil , et al. June 26, 2	2012-06-26
Cytoskeletal Active Rho Kinase Inhibitor Compounds, Composition And Use App 20120046275 - Lampe; John W. ; et al.	2012-02-23
Cytoskeletal active rho kinase inhibitor compounds, composition and use Grant 8,071,779 - Lampe , et al. December 6, 2	2011-12-06
P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis Grant 8,008,274 - Yerxa , et al. August 30, 2	2011-08-30
Ophthalmic Formulation Of Rho Kinase Inhibitor Compound App 20100022517 - Richards; Lori A. ; et al.	2010-01-28
Method For Treating Cardiovascular Diseases Using Rho Kinase Inhibitor Compounds App 20100008968 - Lampe; John W. ; et al.	2010-01-14
Method For Treating Inflammatory Diseases Using Rho Kinase Inhibitor Compounds App 20090325960 - Fulcher; Emilee H. ; et al.	2009-12-31
Method For Treating Pulmonary Diseases Using Rho Kinase Inhibitor Compounds App 20090325958 - Navratil; Tomas ; et al.	2009-12-31
Method For Treating Diseases Associated With Alterations In Cellular Integrity Using Rho Kinase Inhibitor Compounds App 20090325905 - Peterson; Ward M. ; et al.	2009-12-31
Method For Treating Ophthalmic Diseases Using Rho Kinase Inhibitor Compounds App 20090325959 - Vittitow; Jason L. ; et al.	2009-12-31
Method For Treating Neurological And Neuropathic Diseases Using Rho Kinase Inhibitor Compounds App 20090325934 - Navratil; Tomas ; et al.	2009-12-31
P1-(2'-deoxycytidine 5'-)p4-(uridine 5'-)tetraphosphate, Tetra-(alkali Metal) Salt, For Treating Disorders App 20090306010 - Yerxa; Benjamin R. ; et al.	2009-12-10
Degradation-resistant mononucleoside phosphate compounds Grant 7,612,047 - Douglass, III , et al. November 3, 2	2009-11-03
P.sup.1-(2'-deoxycytidine 5'-)P.sup.4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis Grant 7,531,525 - Yerxa , et al. May 12, 2	2009-05-12
Method Of Treating Pulmonary Edema Or Pulmonary Inflammation App 20090098064 - Navratil; Tomas ; et al.	2009-04-16
Degradation-resistant Mononucleoside Phosphate Compounds App 20090076256 - Douglass, III; James G. ; et al.	2009-03-19
Degradation-resistant mononucleoside phosphate compounds Grant 7,435,724 - Douglass, III , et al. October 14, 2	2008-10-14
Cytoskeletal Active Rho Kinase Inhibitor Compounds, Composition And Use App 20080214614 - Lampe; John W. ; et al.	2008-09-04
Degradation-resistant mononucleoside phosphate compounds App 20070244068 - Douglass; James G. III ; et al.	2007-10-18
P1-(2'-deoxycytidine 5'-)p4-(uridine 5'-)tetraphosphate, Tetra-(alkali Metal) Salt, For Treating Disorders App 20070197454 - YERXA; BENJAMIN R. ; et al.	2007-08-23
Method for treating or preventing inflammatory diseases Grant 7,256,183 - Peterson , et al. August 14, 2	2007-08-14
Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof Grant 7,223,744 - Yerxa , et al. May 29, 2	2007-05-29
Compositions for treating epithelial and retinal tissue diseases Grant 7,115,585 - Yerxa , et al. October 3, 2	2006-10-03
Method for reducing intraocular pressure Grant 7,084,128 - Yerxa , et al. August 1, 2	2006-08-01
Method of treating edematous retinal disorders Grant 7,078,391 - Peterson , et al. July 18, 2	2006-07-18
Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof App 20050085439 - Yerxa, Benjamin R. ; et al.	2005-04-21
Method for treating pain Grant 6,881,725 - Yerxa , et al. April 19, 2	2005-04-19
Method for treating retinal degeneration with purinergic receptor agonists Grant 6,864,243 - Peterson March 8, 2	2005-03-08
Method for treating retinal degeneration with purinergic receptor agonists App 20050009778 - Peterson, Ward M.	2005-01-13
Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate Grant 6,818,629 - Peterson , et al. November 16, 2	2004-11-16
Method for reducing intraocular pressure using indole derivatives App 20040198803 - Pintor, Jesus J. ; et al.	2004-10-07
Method for reducing intraocular pressure using indole derivatives Grant 6,730,707 - Pintor , et al. May 4, 2	2004-05-04
Method of treating edematous retinal disorders App 20040077585 - Peterson, Ward M. ; et al.	2004-04-22
Method for reducing intraocular pressure App 20030186928 - Yerxa, Benjamin R. ; et al.	2003-10-02
Method of treating edematous retinal disorders App 20030186917 - Peterson, Ward M. ; et al.	2003-10-02
Method of treating gastrointestinal tract disease with purinergic receptor agonists Grant 6,624,150 - Yerxa , et al. September 23, 2	2003-09-23
Method for treating pain App 20030158147 - Yerxa, Benjamin R. ; et al.	2003-08-21
Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema Grant 6,596,725 - Peterson , et al. July 22, 2	2003-07-22
Method for treating or preventing inflammatory diseases App 20030125299 - Peterson, Ward M. ; et al.	2003-07-03
Compsoitions and methods for treating epithelia and retinal tissue diseases App 20030008834 - Yerxa, Benjamin R. ; et al.	2003-01-09
Method of treating gastrointestinal tract disease with purinergic receptor agonists App 20020052336 - Yerxa, Benjamin R. ; et al.	2002-05-02
Method for reducing intraocular pressure using indole derivatives App 20020037887 - Pintor, Jesus J. ; et al.	2002-03-28
Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema App 20010031743 - Peterson, Ward M. ; et al.	2001-10-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.